Q3 EPS Estimates for AstraZeneca Lifted by Leerink Partnrs

Key Points

• Leerink Partners has raised its earnings estimates for AstraZeneca's Q3 2025 to $1.12 EPS, up from a previous estimate of $1.11 EPS, indicating positive outlook for the company's performance.
• AstraZeneca reported $1.09 EPS for the prior quarter, meeting analyst expectations, and their revenue increased by 16.1% year-over-year to $14.46 billion.
• BNP Paribas set an "outperform" rating for AstraZeneca with a $75.00 price target, while the consensus rating currently stands at "Moderate Buy" with an average target price of $89.00.

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Leerink Partnrs increased their Q3 2025 earnings estimates for AstraZeneca in a report issued on Saturday, August 2nd. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of $1.12 per share for the quarter, up from their previous estimate of $1.11. The consensus estimate for AstraZeneca's current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for AstraZeneca's Q4 2025 earnings at $1.12 EPS, FY2025 earnings at $4.58 EPS and FY2026 earnings at $5.22 EPS.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.09. The firm had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The business's revenue was up 16.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.24 earnings per share.

A number of other analysts also recently issued reports on AZN. BNP Paribas initiated coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research report on Wednesday, July 9th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $89.00.

AstraZeneca Stock Up 0.9%

NASDAQ:AZN opened at $74.59 on Tuesday. AstraZeneca has a 1-year low of $61.24 and a 1-year high of $87.68. The company has a 50-day moving average of $71.63 and a 200 day moving average of $71.50. The firm has a market cap of $231.33 billion, a PE ratio of 28.04, a price-to-earnings-growth ratio of 1.36 and a beta of 0.36. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67.

Institutional Trading of AstraZeneca

Large investors have recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in AstraZeneca by 93.2% in the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock worth $379,000 after buying an additional 2,789 shares during the last quarter. American Assets Inc. acquired a new position in AstraZeneca during the 4th quarter worth approximately $426,000. Norges Bank acquired a new position in AstraZeneca during the 4th quarter worth approximately $1,073,000. Geode Capital Management LLC lifted its position in AstraZeneca by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 498,831 shares of the company's stock worth $32,683,000 after acquiring an additional 5,384 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in AstraZeneca by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 30,759 shares of the company's stock worth $2,015,000 after acquiring an additional 2,158 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be issued a $0.505 dividend. The ex-dividend date of this dividend is Friday, August 8th. This represents a yield of 200.0%. AstraZeneca's dividend payout ratio is 77.44%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.